J&J TREMFYA Pediatric Psoriasis EC Approval Targets First IL-23 Indication
Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has extended the...
Takeda Zasocitinib TYK2 Phase III Shows Positive Psoriasis Results
Takeda Pharmaceutical Company (TYO: 4502, NYSE: TAK) announced positive topline results from two pivotal Phase III...
Lilly Imlunestrant Breast-Cancer EMBER-3 Shows 38% Risk Reduction
Eli Lilly (NYSE: LLY) announced updated results from the Phase III EMBER‑3 clinical trial evaluating its...
IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully
IVIEW Therapeutics Inc. announced the successful treatment of the first patient with primary open-angle glaucoma...
Novartis MSD Sanofi TrumpRx Deal Targets Medicaid Pricing
Novartis (NYSE: NVS), MSD (NYSE: MRK), and Sanofi (NASDAQ: SNY) announced partnerships with the U.S....
Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
Novabio Therapeutics, a China‑based clinical‑stage biotech, announced the successful completion of first patient dosing in...
Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
Grand Pharmaceutical Group Limited (HKG: 0512) announced that its China‑based Phase III clinical trial for TLX591‑CDx...
MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
Medtronic plc (NYSE: MDT) announced that its diabetes business, which will operate under the name MiniMed,...
Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming entered into an exclusive global licensing...
Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
Merck KGaA (ETR: MRK) announced that China’s National Medical Products Administration (NMPA) granted priority review approval...
GSK’s Nucala Wins China Approval as First IL‑5 Biologic for COPD
GlaxoSmithKline (GSK, NYSE: GSK) China announced that China’s National Medical Products Administration (NMPA) approved Nucala...
EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B
Epigenic Therapeutics (Shanghai) Biotechnology Co., Ltd., a clinical‑stage biotech focused on epigenetic modulation therapies, announced...
SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target
SanegeneBio, a clinical‑stage RNAi therapeutics company, announced that China’s National Medical Products Administration (NMPA) approved...
Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a strategic collaboration with...
BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that the U.S. Food and Drug...
BeOne Medicines Names Dual Presidents in Leadership Overhaul
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced a leadership restructuring, appointing Dr. Lai...
Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline
Leadingtac Pharmaceutical Co., Ltd. announced the successful completion of its Series B financing round, raising...
TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor
TransThera Sciences (Nanjing), Inc. (HKG: 2617) announced that China’s National Medical Products Administration (NMPA) formally...
Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China
Bio‑Thera Solutions (SHA: 688177) submitted a New Drug Application (NDA) to China’s National Medical Products...
Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity
Novo Nordisk A/S (NYSE: NVO) submitted a New Drug Application (NDA) to the U.S. FDA...